216 related articles for article (PubMed ID: 32343721)
1. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.
Hung MH; Chen YL; Chen LJ; Chu PY; Hsieh FS; Tsai MH; Shih CT; Chao TI; Huang CY; Chen KF
Cell Death Dis; 2019 May; 10(6):420. PubMed ID: 31142735
[TBL] [Abstract][Full Text] [Related]
3. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
5. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
[TBL] [Abstract][Full Text] [Related]
7. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
8. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
[TBL] [Abstract][Full Text] [Related]
9. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
Otsuka H; Yokomizo H; Nakamura S; Izumi Y; Takahashi M; Obara S; Nakao M; Ikeda Y; Sato N; Sakamoto R; Miyachi Y; Miyazawa T; Bamba T; Ogawa Y
Biochem J; 2022 Feb; 479(3):425-444. PubMed ID: 35048967
[TBL] [Abstract][Full Text] [Related]
11. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
Zeng Y; Jiang H; Zhang X; Xu J; Wu X; Xu Q; Cai W; Ying H; Zhou R; Ding Y; Ying K; Song X; Chen Z; Zeng L; Zhao L; Yu F
Free Radic Biol Med; 2023 Nov; 208():571-586. PubMed ID: 37696420
[TBL] [Abstract][Full Text] [Related]
13. The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following
Korkmaz-Icöz S; Kocer C; Sayour AA; Kraft P; Benker MI; Abulizi S; Georgevici AI; Brlecic P; Radovits T; Loganathan S; Karck M; Szabó G
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360539
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy.
Angelopoulou A; Kolokithas-Ntoukas A; Papaioannou L; Kakazanis Z; Khoury N; Zoumpourlis V; Papatheodorou S; Kardamakis D; Bakandritsos A; Hatziantoniou S; Avgoustakis K
Nanomedicine (Lond); 2018 Oct; 13(19):2435-2454. PubMed ID: 30311542
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
18. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
19. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
VanDerStad LR; Wyatt EC; Vaughan RA
Diabet Med; 2024 May; 41(5):e15271. PubMed ID: 38140911
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
So EC; Liu PY; Wu SN
Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
